title: Beyond lipodystrophy: will toxicity issues ever outweigh the benefits of HAART?
authors.forename: Stefano
authors.initials: S
authors.lastname: Vella
authors.forename: Lucia
authors.initials: L
authors.lastname: Palmisano
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced* / Q000821:virology; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000139:chemically induced; D011247:Pregnancy; D012737:Sex Factors; D012907:Smoking
chemical_list: D019380:Anti-HIV Agents